vs
Beam Therapeutics Inc.（BEAM）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是RE/MAX Holdings, Inc.的1.6倍（$114.1M vs $71.1M），Beam Therapeutics Inc.净利率更高（214.1% vs 2.0%，领先212.1%），Beam Therapeutics Inc.同比增速更快（279.5% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-87.0M）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
BEAM vs RMAX — 直观对比
营收规模更大
BEAM
是对方的1.6倍
$71.1M
营收增速更快
BEAM
高出281.4%
-1.8%
净利率更高
BEAM
高出212.1%
2.0%
自由现金流更多
RMAX
多$120.5M
$-87.0M
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $71.1M |
| 净利润 | $244.3M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -15.3% | 13.1% |
| 净利率 | 214.1% | 2.0% |
| 营收同比 | 279.5% | -1.8% |
| 净利润同比 | 370.4% | -75.2% |
| 每股收益（稀释后） | $2.53 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMRMAX
| Q4 25 | $114.1M | $71.1M | ||
| Q3 25 | — | $73.2M | ||
| Q2 25 | — | $72.8M | ||
| Q1 25 | — | $74.5M | ||
| Q4 24 | — | $72.5M | ||
| Q3 24 | — | $78.5M | ||
| Q2 24 | — | $78.5M | ||
| Q1 24 | — | $78.3M |
净利润BEAMRMAX
| Q4 25 | $244.3M | $1.4M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | — | $4.7M | ||
| Q1 25 | — | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | — | $966.0K | ||
| Q2 24 | — | $3.7M | ||
| Q1 24 | — | $-3.4M |
营业利润率BEAMRMAX
| Q4 25 | -15.3% | 13.1% | ||
| Q3 25 | — | 25.0% | ||
| Q2 25 | — | 19.3% | ||
| Q1 25 | — | 7.2% | ||
| Q4 24 | — | 5.9% | ||
| Q3 24 | — | 19.4% | ||
| Q2 24 | — | 20.6% | ||
| Q1 24 | — | 5.8% |
净利率BEAMRMAX
| Q4 25 | 214.1% | 2.0% | ||
| Q3 25 | — | 5.4% | ||
| Q2 25 | — | 6.4% | ||
| Q1 25 | — | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 4.7% | ||
| Q1 24 | — | -4.3% |
每股收益（稀释后）BEAMRMAX
| Q4 25 | $2.53 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $1.2B | $452.4M |
| 总资产 | $1.5B | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资BEAMRMAX
| Q4 25 | $1.2B | $118.7M | ||
| Q3 25 | — | $107.5M | ||
| Q2 25 | — | $94.3M | ||
| Q1 25 | — | $89.1M | ||
| Q4 24 | — | $96.6M | ||
| Q3 24 | — | $83.8M | ||
| Q2 24 | — | $66.1M | ||
| Q1 24 | — | $82.1M |
总债务BEAMRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益BEAMRMAX
| Q4 25 | $1.2B | $452.4M | ||
| Q3 25 | — | $448.1M | ||
| Q2 25 | — | $442.4M | ||
| Q1 25 | — | $433.5M | ||
| Q4 24 | — | $429.5M | ||
| Q3 24 | — | $423.1M | ||
| Q2 24 | — | $418.4M | ||
| Q1 24 | — | $412.0M |
总资产BEAMRMAX
| Q4 25 | $1.5B | $582.5M | ||
| Q3 25 | — | $582.2M | ||
| Q2 25 | — | $574.8M | ||
| Q1 25 | — | $571.4M | ||
| Q4 24 | — | $581.6M | ||
| Q3 24 | — | $578.6M | ||
| Q2 24 | — | $571.4M | ||
| Q1 24 | — | $566.7M |
负债/权益比BEAMRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | $33.5M |
| 自由现金流率自由现金流/营收 | -76.3% | 47.1% |
| 资本支出强度资本支出/营收 | 3.3% | 10.4% |
| 现金转化率经营现金流/净利润 | -0.34× | 28.39× |
| 过去12个月自由现金流最近4个季度 | — | $56.8M |
8季度趋势，按日历期对齐
经营现金流BEAMRMAX
| Q4 25 | $-83.3M | $40.9M | ||
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $4.6M | ||
| Q1 25 | — | $5.7M | ||
| Q4 24 | — | $59.7M | ||
| Q3 24 | — | $17.6M | ||
| Q2 24 | — | $15.9M | ||
| Q1 24 | — | $9.4M |
自由现金流BEAMRMAX
| Q4 25 | $-87.0M | $33.5M | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | — | $2.9M | ||
| Q1 25 | — | $4.0M | ||
| Q4 24 | — | $53.0M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $14.0M | ||
| Q1 24 | — | $6.8M |
自由现金流率BEAMRMAX
| Q4 25 | -76.3% | 47.1% | ||
| Q3 25 | — | 22.4% | ||
| Q2 25 | — | 4.0% | ||
| Q1 25 | — | 5.3% | ||
| Q4 24 | — | 73.2% | ||
| Q3 24 | — | 20.8% | ||
| Q2 24 | — | 17.8% | ||
| Q1 24 | — | 8.6% |
资本支出强度BEAMRMAX
| Q4 25 | 3.3% | 10.4% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 2.2% | ||
| Q1 25 | — | 2.3% | ||
| Q4 24 | — | 9.1% | ||
| Q3 24 | — | 1.7% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 3.3% |
现金转化率BEAMRMAX
| Q4 25 | -0.34× | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
